Edgewise Therapeutics said it will sell sevasemten and its muscular dystrophy business to Servier for as much as $2.65 billion, including $1.55 billion in upfront cash and up to $1.1 billion in regulatory and commercial milestones.
The deal shifts Edgewise into a cardiovascular-focused company. After closing, its pipeline will center on EDG-7500 for hypertrophic cardiomyopathy, EDG-15400 for HFpEF, and EDG-003 for an undisclosed target.
The company said the $1.55 billion upfront payment, combined with its existing cash, is expected to fully fund EDG-7500 development through potential approval. Edgewise also said the cash will provide additional room to advance EDG-15400 and broaden the cardiovascular pipeline.
Edgewise reiterated that it plans to report 12-week data from the CIRRUS-HCM Part D study of EDG-7500 in the second quarter of 2026. Those data are expected to include safety, echocardiographic, biomarker and patient-reported outcomes across both obstructive and nonobstructive hypertrophic cardiomyopathy. The company said those results will inform Phase 3 design, with initiation targeted for the fourth quarter of 2026.
In parallel, Edgewise said it remains on track to start a Phase 2 trial of EDG-15400 in HFpEF.
The company said Servier will acquire all rights to sevasemten, including intellectual property, know-how, key agreements, regulatory filings and clinical data needed to run the muscular dystrophy business. Employees primarily supporting that business will receive comparable offers from Servier.
Sevasemten is in late-stage development for Becker and Duchenne muscular dystrophy. Edgewise said the Grand Canyon pivotal cohort in Becker is fully enrolled with 175 participants and is powered at greater than 98% to show a statistically significant difference versus placebo. Top-line data are expected in the fourth quarter of 2026.
Over more than three years of clinical studies, the company said sevasemten has shown sustained disease stabilization, with participants in the MESA open-label extension maintaining stable North Star Ambulatory Assessment scores. Edgewise also said the drug has not required discontinuations or dose reductions because of adverse events.
The transaction was unanimously approved by the boards of Edgewise and Servier and is expected to close in the third quarter of 2026. Following these announcements, the company's shares moved 17.52%, and are now trading at a price of $40.145. For more information, read the company's full 8-K submission here.
